Evidence map›Paper›PMID 40593813›Full record

ArticleNature communications2025

Suppression of gut colonization by multidrug-resistant Escherichia coli clinical isolates through cooperative niche exclusion.

Marie Wende, Lisa Osbelt, Lea Eisenhard, Till Robin Lesker, Bamu F Damaris, Uthayakumar Mutukumarasamy, Agata Bielecka, Éva D H Almási, Katrin Anja Winter, Jennifer Schauer and 6 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Complete genome sequence ofMicrobiology resource announcements · 2026
    Article
  6. Review
  7. [Advances in the diagnosis and treatment of patients with multidrug-resistant bacterial infections combined with severe liver disease].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026
    Review
  8. Article
  9. Review
  10. A comparativeFrontiers in microbiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Marie WendeDepartment of Microbial Immune Regulation, Helmholtz Center for Infection Research, Braunschweig, Germany.
Lisa Osbelt *Department of Microbial Immune Regulation, Helmholtz Center for Infection Research, Braunschweig, Germany.ORCID http://orcid.org/0000-0002-4862-650X
Lea Eisenhard *Department of Microbial Immune Regulation, Helmholtz Center for Infection Research, Braunschweig, Germany.
Till Robin LeskerDepartment of Microbial Immune Regulation, Helmholtz Center for Infection Research, Braunschweig, Germany.
Bamu F DamarisInstitute for Molecular Bacteriology, TWINCORE Centre for Experimental and Clinical Infection Research, a joint venture between the Hannover Medical School (MHH) and the Helmholtz Centre for Infection Research (HZI), Hannover, Germany.
Uthayakumar MutukumarasamyDepartment of Microbial Immune Regulation, Helmholtz Center for Infection Research, Braunschweig, Germany.
Agata BieleckaDepartment of Microbial Immune Regulation, Helmholtz Center for Infection Research, Braunschweig, Germany.
Éva D H AlmásiDepartment of Microbial Immune Regulation, Helmholtz Center for Infection Research, Braunschweig, Germany.ORCID http://orcid.org/0000-0001-5042-5478
Katrin Anja WinterDepartment of Microbial Immune Regulation, Helmholtz Center for Infection Research, Braunschweig, Germany.ORCID http://orcid.org/0009-0005-4180-0244
Jennifer SchauerNational Reference Centre for Multidrug-resistant Gram-negative Bacteria, Department of Medical Microbiology, Ruhr-University Bochum, Bochum, Germany.
Niels PfennigwerthNational Reference Centre for Multidrug-resistant Gram-negative Bacteria, Department of Medical Microbiology, Ruhr-University Bochum, Bochum, Germany.
Sören GatermannNational Reference Centre for Multidrug-resistant Gram-negative Bacteria, Department of Medical Microbiology, Ruhr-University Bochum, Bochum, Germany.ORCID http://orcid.org/0000-0002-8662-218X
Katharina SchauflerHelmholtz Institute for One Health, Helmholtz Center for Infection Research HZI, Department of Epidemiology and Ecology of Antimicrobial Resistance, Greifswald, Germany.ORCID http://orcid.org/0000-0002-2669-8799
Dirk SchlüterCluster of Excellence RESIST (EXC 2155), Hannover Medical School, Hannover, Germany.ORCID http://orcid.org/0000-0003-1478-3328
Marco GalardiniInstitute for Molecular Bacteriology, TWINCORE Centre for Experimental and Clinical Infection Research, a joint venture between the Hannover Medical School (MHH) and the Helmholtz Centre for Infection Research (HZI), Hannover, Germany.ORCID http://orcid.org/0000-0003-2018-8242
Till StrowigDepartment of Microbial Immune Regulation, Helmholtz Center for Infection Research, Braunschweig, Germany. till.strowig@helmholtz-hzi.de.ORCID http://orcid.org/0000-0003-0185-1459

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human gut colonization by multi-drug resistant Enterobacterales (MDR-E) poses a risk for subsequent infections. Because of the collateral damage antibiotics cause to the microbiota, microbiome-based interventions aimed at promoting decolonization have garnered interest. In this study, we evaluate the strain-specific potential of 430 commensal Escherichia coli isolates to inhibit the growth of an MDR E. coli strain. Comparative analyses using in vitro, ex vivo, and mouse models reveal that only a subset of commensal strains can facilitate gut decolonization. Bioinformatic and experimental analyses of the antagonism among representative strains demonstrate that both direct and indirect carbohydrate competition contribute to niche exclusion between E. coli strains. Finally, the combination of a protective E. coli strain with a Klebsiella oxytoca strain enhances the inhibitory potential against metabolically diverse MDR E. coli strains and additional MDR-E species, highlighting that rationally designed metabolically complementary approaches can contribute to developing next-generation probiotics with broad-spectrum activity.

Indexed as

Drug Resistance, Multiple, BacterialEscherichia coliEscherichia coli InfectionsGastrointestinal MicrobiomeAnimalsAnti-Bacterial AgentsAntibiosisFemaleHumansKlebsiella oxytocaMiceProbioticsAnti-Bacterial Agents

Identifiers

PMID40593813
PMCPMC12215308

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.